Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Invivyd, Inc. (IVVD : NSDQ)

• Company Description    INVIVYD INC. is a biopharmaceutical company. It involved in developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. INVIVYD INC., formerly known as Adagio Therapeutics, is based in WALTHAM, Mass. Number of Employees: 100

• Price / Volume Information    Yesterday's Closing Price: $1.23 Daily Weekly Monthly 20 Day Moving Average: 14,540,605 shares Shares Outstanding: 120.14 (millions) Market Capitalization: $147.78 (millions) Beta: 0.55 52 Week High: $2.74 52 Week Low: $0.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 53.88% 51.11% 12 Week 64.22% 49.10% Year To Date 177.59% 147.85%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1601 TRAPELO ROAD SUITE 178 - WALTHAM,MA 02451 USA ph: 781-819-0080 fax: - investors@invivyd.com https://invivyd.com

• General Corporate Information    Officers Marc Elia - Chairman of the Board of Directors William Duke - Chief Financial Officer Tamsin Berry - Director Srishti Gupta - Director Christine Lindenboom - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00534A102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 120.14 Most Recent Split Date: (:1) Beta: 0.55 Market Capitalization: $147.78 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.40 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.45 Price/Cash Flow: - Price / Sales: 3.20 EPS Growth vs. Year Ago Period: 70.00% vs. Previous Quarter: 14.29% Sales Growth vs. Year Ago Period: 420.58% vs. Previous Quarter: 4.26% ROE 06/30/25 - -177.89 03/31/25 - -165.24 12/31/24 - -144.67 ROA 06/30/25 - -90.96 03/31/25 - -99.71 12/31/24 - -99.33 Current Ratio 06/30/25 - 1.33 03/31/25 - 1.53 12/31/24 - 2.04 Quick Ratio 06/30/25 - 1.33 03/31/25 - 1.53 12/31/24 - 1.62 Operating Margin 06/30/25 - -238.33 03/31/25 - -389.01 12/31/24 - - Net Margin 06/30/25 - -238.33 03/31/25 - -389.01 12/31/24 - - Pre-Tax Margin 06/30/25 - -238.33 03/31/25 - -389.01 12/31/24 - -669.42 Book Value 06/30/25 - 0.36 03/31/25 - 0.45 12/31/24 - 0.56 Inventory Turnover 06/30/25 - 0.23 03/31/25 - 0.17 12/31/24 - 0.11 Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©